Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RP-3467 |
| Synonyms | |
| Therapy Description |
RP-3467 inhibits DNA polymerase theta (POLQ), which may prevent the repair of DNA-double stranded breaks, resulting in increased apoptosis and decreased proliferation of tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RP-3467 | RP3467|RP 3467 | RP-3467 inhibits DNA polymerase theta (POLQ), which may prevent the repair of DNA-double stranded breaks, resulting in increased apoptosis and decreased proliferation of tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06560632 | Phase I | Olaparib + RP-3467 RP-3467 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) | Active, not recruiting | USA | 0 |